Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D gr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Smith, Jordan L., Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2015
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394293/
https://ncbi.nlm.nih.gov/pubmed/25805818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1415569112
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados